Literature DB >> 9368840

Collateral projections from striatonigral neurons to substance P receptor-expressing intrinsic neurons in the striatum of the rat.

T Lee1, T Kaneko, R Shigemoto, S Nomura, N Mizuno.   

Abstract

It is well known that striatonigral neurons produce substance P (SP); however, no SP receptor (SPR) has so far been found in the substantia nigra. On the other hand, a previous study in the rat striatum indicated that SPR was expressed only in cholinergic or somatostatinergic intrinsic neurons (Kaneko et al. [1993] Brain Res. 631:297-303). Thus, it was assumed that SP produced by striatonigral neurons might be released through their intrastriatal axon collaterals to act upon intrinsic neurons in the striatum. To confirm this assumption, the distribution of axon collaterals of striatonigral neurons was examined in the striatum of the rat. The experiments were performed on brain slices by combining retrograde labeling with tetramethylrhodamine-dextran amine, electrophysiological recording, intracellular staining with biocytin, and immunocytochemistry for SPR. The distribution of axons of cholinergic striatal neurons (a group of SP-negative intrinsic striatal neurons) was also examined. It was observed that 16% of varicosities of intrastriatal axon collaterals of striatonigral neurons, as well as 6% of axonal varicosities of cholinergic neurons, were in close apposition to dendrites and cell bodies of SPR-immunoreactive striatal neurons. Since SPR-immunoreactive striatal neurons constituted only 2.7% of the total population of striatal neurons (Kaneko et al. [1993] Brain Res. 631:297-303), it appeared that axonal varicosities of striatonigral neurons were preferentially apposed to SPR-immunoreactive striatal neurons and that the varicosities in close apposition to SPR-immunoreactive neurons were derived more frequently from striatonigral neurons than from cholinergic interneurons. Confocal laser scanning microscopy indicated that axonal varicosities in close apposition to SPR-immunoreactive cells showed synaptophysin immunoreactivity, a marker of synaptic vesicles. In intrastriatal axons of striatonigral neurons, it was further revealed from electron microscopy that axonal varicosities in close apposition to SPR-immunoreactive dendrites, at least a part of them, made synapses of the symmetric type. Striatonigral neurons might release SP preferentially around cholinergic or somatostatinergic intrinsic neurons to regulate them through SP-SPR interactions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9368840     DOI: 10.1002/(sici)1096-9861(19971117)388:2<250::aid-cne5>3.0.co;2-0

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  5 in total

1.  Distinct Subpopulations of Nucleus Accumbens Dynorphin Neurons Drive Aversion and Reward.

Authors:  Ream Al-Hasani; Jordan G McCall; Gunchul Shin; Adrian M Gomez; Gavin P Schmitz; Julio M Bernardi; Chang-O Pyo; Sung Il Park; Catherine M Marcinkiewcz; Nicole A Crowley; Michael J Krashes; Bradford B Lowell; Thomas L Kash; John A Rogers; Michael R Bruchas
Journal:  Neuron       Date:  2015-09-02       Impact factor: 17.173

Review 2.  Neuronal pathways linking substance P to drug addiction and stress.

Authors:  K G Commons
Journal:  Brain Res       Date:  2009-11-11       Impact factor: 3.252

3.  Developmental Profile of Brain Neprilysin Expression Correlates with Olfactory Behaviour of Rats.

Authors:  Dimitrii S Vasilev; Nadezhda M Dubrovskaya; Igor A Zhuravin; Natalia N Nalivaeva
Journal:  J Mol Neurosci       Date:  2021-01-12       Impact factor: 3.444

4.  Reconstructing the three-dimensional GABAergic microcircuit of the striatum.

Authors:  Mark D Humphries; Ric Wood; Kevin Gurney
Journal:  PLoS Comput Biol       Date:  2010-11-24       Impact factor: 4.475

5.  Shifting responsibly: the importance of striatal modularity to reinforcement learning in uncertain environments.

Authors:  Ken-Ichi Amemori; Leif G Gibb; Ann M Graybiel
Journal:  Front Hum Neurosci       Date:  2011-05-27       Impact factor: 3.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.